{"id":"https://openalex.org/W4288950951","doi":"https://doi.org/10.1016/j.ejca.2022.03.016","title":"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer","display_name":"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer","publication_year":2022,"publication_date":"2022-07-31","ids":{"openalex":"https://openalex.org/W4288950951","doi":"https://doi.org/10.1016/j.ejca.2022.03.016","pmid":"https://pubmed.ncbi.nlm.nih.gov/35922251"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejca.2022.03.016","doi":"https://doi.org/10.1016/j.ejca.2022.03.016","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2022.03.016","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.ejca.2022.03.016","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067053417","display_name":"Ana Oaknin","orcid":"https://orcid.org/0000-0002-3592-7194","observed_orcids":["https://orcid.org/0000-0002-3592-7194"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Ana Oaknin","raw_affiliation_strings":["Gynaecologic Cancer Programme, Vall D'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall D'Hebron, Vall D'Hebron Barcelona Hospital Campus, Barcelona, Spain. Electronic address: aoaknin@vhio.net","Gynaecologic Cancer Programme, Vall D'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall D'Hebron, Vall D'Hebron Barcelona Hospital Campus, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gynaecologic Cancer Programme, Vall D'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall D'Hebron, Vall D'Hebron Barcelona Hospital Campus, Barcelona, Spain. Electronic address: aoaknin@vhio.net","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]},{"raw_affiliation_string":"Gynaecologic Cancer Programme, Vall D'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall D'Hebron, Vall D'Hebron Barcelona Hospital Campus, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014611244","display_name":"Bradley J. Monk","orcid":"https://orcid.org/0000-0001-6985-0159","observed_orcids":["https://orcid.org/0000-0001-6985-0159","https://orcid.org/0000-0002-0680-3184"]},"institutions":[{"id":"https://openalex.org/I114493937","display_name":"Creighton University","ror":"https://ror.org/05wf30g94","country_code":"US","type":"education","lineage":["https://openalex.org/I114493937"]},{"id":"https://openalex.org/I138006243","display_name":"University of Arizona","ror":"https://ror.org/03m2x1q45","country_code":"US","type":"education","lineage":["https://openalex.org/I138006243"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]},{"id":"https://openalex.org/I4210162453","display_name":"Arizona Oncology","ror":"https://ror.org/05c1xy536","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bradley J. Monk","raw_affiliation_strings":["Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA","institution_ids":["https://openalex.org/I114493937","https://openalex.org/I138006243","https://openalex.org/I4210151469","https://openalex.org/I4210162453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058535647","display_name":"Ignace B. Vergote","orcid":"https://orcid.org/0000-0002-7589-8981","observed_orcids":["https://orcid.org/0000-0002-7589-8981"]},"institutions":[{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Ignace Vergote","raw_affiliation_strings":["Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University Hospitals, KU Leuven, Leuven, Belgium"],"raw_orcid":"https://orcid.org/0000-0002-7589-8981","affiliations":[{"raw_affiliation_string":"Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University Hospitals, KU Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031354838","display_name":"Andr\u00e9ia Cristina de Melo","orcid":"https://orcid.org/0000-0002-1201-4333","observed_orcids":["https://orcid.org/0000-0002-1201-4333"]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Andreia Cristina de Melo","raw_affiliation_strings":["Division of Clinical Research and Technological Development, Hospital Do C\u00e2ncer II, Brazilian National Cancer Institute, Rio de Janeiro, Brazil"],"raw_orcid":"https://orcid.org/0000-0002-1201-4333","affiliations":[{"raw_affiliation_string":"Division of Clinical Research and Technological Development, Hospital Do C\u00e2ncer II, Brazilian National Cancer Institute, Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053719602","display_name":"Yong\u2010Man Kim","orcid":"https://orcid.org/0000-0003-3225-5748","observed_orcids":["https://orcid.org/0000-0003-3225-5748"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]},{"id":"https://openalex.org/I40542001","display_name":"University of Ulsan","ror":"https://ror.org/02c2f8975","country_code":"KR","type":"education","lineage":["https://openalex.org/I40542001"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Yong-Man Kim","raw_affiliation_strings":["Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, South Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, South Korea","institution_ids":["https://openalex.org/I2801680663","https://openalex.org/I40542001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024415050","display_name":"Alla S. Lisyanskaya","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alla S. Lisyanskaya","raw_affiliation_strings":["St Petersburg State Budgetary Institution of Healthcare, St Petersburg, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St Petersburg State Budgetary Institution of Healthcare, St Petersburg, Russia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058998735","display_name":"Vanessa Samou\u00eblian","orcid":"https://orcid.org/0000-0003-4409-147X","observed_orcids":["https://orcid.org/0000-0003-4409-147X"]},"institutions":[{"id":"https://openalex.org/I4210142730","display_name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al","ror":"https://ror.org/0410a8y51","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4210142730","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I70931966","display_name":"Universit\u00e9 de Montr\u00e9al","ror":"https://ror.org/0161xgx34","country_code":"CA","type":"education","lineage":["https://openalex.org/I70931966"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Vanessa Samou\u00eblian","raw_affiliation_strings":["Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Centre Hospitalier de L'Universit\u00e9 de Montr\u00e9al (CHUM), Centre de Recherche Du Centre Hospitalier de L'Universit\u00e9 de Montr\u00e9al (CRCHUM) and Universit\u00e9 de Montr\u00e9al, Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Centre Hospitalier de L'Universit\u00e9 de Montr\u00e9al (CHUM), Centre de Recherche Du Centre Hospitalier de L'Universit\u00e9 de Montr\u00e9al (CRCHUM) and Universit\u00e9 de Montr\u00e9al, Montreal, Canada","institution_ids":["https://openalex.org/I4210142730","https://openalex.org/I70931966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055261519","display_name":"Hee Seung Kim","orcid":"https://orcid.org/0000-0001-6876-8671","observed_orcids":["https://orcid.org/0000-0001-6876-8671"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Hee Seung Kim","raw_affiliation_strings":["Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea","institution_ids":["https://openalex.org/I139264467"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053761748","display_name":"Evgeniy A. Gotovkin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evgeniy A. Gotovkin","raw_affiliation_strings":["State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary, Ivanovo, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary, Ivanovo, Russia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091843646","display_name":"Fernanda Damian","orcid":"https://orcid.org/0000-0003-4651-3357","observed_orcids":["https://orcid.org/0000-0003-4651-3357"]},"institutions":[{"id":"https://openalex.org/I4210137261","display_name":"Hospital S\u00e3o Lucas da PUCRS","ror":"https://ror.org/0353n6963","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210137261"]},{"id":"https://openalex.org/I45643870","display_name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul","ror":"https://ror.org/025vmq686","country_code":"BR","type":"education","lineage":["https://openalex.org/I45643870"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Fernanda Damian","raw_affiliation_strings":["Centro de Pesquisa Em Oncologia, Hospital S\u00e3o Lucas, Pontifical Catholic University of Rio Grande Do Sul, Porto Alegre, Brazil"],"raw_orcid":"https://orcid.org/0000-0003-4651-3357","affiliations":[{"raw_affiliation_string":"Centro de Pesquisa Em Oncologia, Hospital S\u00e3o Lucas, Pontifical Catholic University of Rio Grande Do Sul, Porto Alegre, Brazil","institution_ids":["https://openalex.org/I4210137261","https://openalex.org/I45643870"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037997481","display_name":"Chih\u2010Long Chang","orcid":"https://orcid.org/0000-0003-3981-9366","observed_orcids":["https://orcid.org/0000-0003-3981-9366"]},"institutions":[{"id":"https://openalex.org/I2802753785","display_name":"Mackay Memorial Hospital","ror":"https://ror.org/015b6az38","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I2802753785"]},{"id":"https://openalex.org/I35926432","display_name":"Mackay Medical University","ror":"https://ror.org/00t89kj24","country_code":"TW","type":"education","lineage":["https://openalex.org/I35926432"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Chih-Long Chang","raw_affiliation_strings":["Department of Obstetrics and Gynecology, Mackay Memorial Hospital and Department of Medicine, Mackay Medical College, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Obstetrics and Gynecology, Mackay Memorial Hospital and Department of Medicine, Mackay Medical College, Taipei, Taiwan","institution_ids":["https://openalex.org/I2802753785","https://openalex.org/I35926432"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018910129","display_name":"Shunji Takahashi","orcid":"https://orcid.org/0000-0002-5031-1953","observed_orcids":["https://orcid.org/0000-0002-5031-1953"]},"institutions":[{"id":"https://openalex.org/I4210137039","display_name":"The Cancer Institute Hospital","ror":"https://ror.org/03md8p445","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210137039"]},{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shunji Takahashi","raw_affiliation_strings":["Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I4210137039","https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103281201","display_name":"Jingjin Li","orcid":"https://orcid.org/0009-0000-3867-990X","observed_orcids":["https://orcid.org/0009-0000-3867-990X"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jingjin Li","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026335885","display_name":"Melissa Divya Mathias","orcid":"https://orcid.org/0000-0001-6026-601X","observed_orcids":["https://orcid.org/0000-0001-6026-601X"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Mathias","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072271778","display_name":"Matthew G. Fury","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew G. Fury","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089739735","display_name":"Cristina Ivanescu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cristina Ivanescu","raw_affiliation_strings":["IQVIA, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IQVIA, Amsterdam, Netherlands","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009151561","display_name":"Matthew D. Reaney","orcid":"https://orcid.org/0000-0003-2918-722X","observed_orcids":["https://orcid.org/0000-0003-2918-722X"]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew Reaney","raw_affiliation_strings":["IQVIA, London, UK"],"raw_orcid":"https://orcid.org/0000-0003-2918-722X","affiliations":[{"raw_affiliation_string":"IQVIA, London, UK","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021974605","display_name":"Patrick R. LaFontaine","orcid":"https://orcid.org/0000-0002-5212-5513","observed_orcids":["https://orcid.org/0000-0002-5212-5513"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick R. LaFontaine","raw_affiliation_strings":["Sanofi, Cambridge, MA, USA"],"raw_orcid":"https://orcid.org/0000-0002-5212-5513","affiliations":[{"raw_affiliation_string":"Sanofi, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031475492","display_name":"Israel Lowy","orcid":"https://orcid.org/0000-0002-5421-2485","observed_orcids":["https://orcid.org/0000-0002-5421-2485"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Israel Lowy","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004596365","display_name":"James Harnett","orcid":"https://orcid.org/0000-0002-4217-0118","observed_orcids":["https://orcid.org/0000-0002-4217-0118"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Harnett","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016395117","display_name":"Chieh-I Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chieh-I Chen","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055050872","display_name":"Krishnansu S. Tewari","orcid":"https://orcid.org/0000-0002-8417-7000","observed_orcids":["https://orcid.org/0000-0002-8417-7000"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Krishnansu S. Tewari","raw_affiliation_strings":["Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of California, Irvine, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of California, Irvine, CA, USA","institution_ids":["https://openalex.org/I204250578"]}]}],"institutions":[],"countries_distinct_count":9,"institutions_distinct_count":22,"corresponding_author_ids":["https://openalex.org/A5067053417"],"corresponding_institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":7.3736,"has_fulltext":true,"cited_by_count":38,"citation_normalized_percentile":{"value":0.98240174,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":99},"biblio":{"volume":"174","issue":null,"first_page":"299","last_page":"309"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.9160000085830688,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.9160000085830688,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.03269999846816063,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10146","display_name":"Cervical Cancer and HPV Research","score":0.025100000202655792,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cemiplimab","display_name":"cemiplimab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/recurrent-cervical-cancer","display_name":"recurrent cervical cancer","score":0.9959999918937683},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.8029999732971191},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9929999709129333},{"id":"https://openalex.org/keywords/physical-functioning","display_name":"physical function","score":0.9860000014305115},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.800000011920929},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.6370000243186951},{"id":"https://openalex.org/keywords/squamous-cell-carcinoma","display_name":"squamous cell carcinoma","score":0.8109999895095825},{"id":"https://openalex.org/keywords/adenocarcinoma","display_name":"adenocarcinoma","score":0.8259999752044678},{"id":"https://openalex.org/keywords/role-functioning","display_name":"role functioning","score":0.7490000128746033},{"id":"https://openalex.org/keywords/loss-of-appetite","display_name":"appetite loss","score":0.8740000128746033},{"id":"https://openalex.org/keywords/pain","display_name":"pain","score":0.8500000238418579},{"id":"https://openalex.org/keywords/global-health-status","display_name":"global health status","score":0.546999990940094}],"concepts":[{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.7267450094223022},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7090222835540771},{"id":"https://openalex.org/C2778220009","wikidata":"https://www.wikidata.org/wiki/Q160105","display_name":"Cervical cancer","level":3,"score":0.5255804657936096},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5031887888908386},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.42624184489250183},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4242899417877197},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40835073590278625},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3685528635978699},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.36517366766929626},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000071066","descriptor_name":"Patient Reported Outcome Measures","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D010146","descriptor_name":"Pain","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.ejca.2022.03.016","doi":"https://doi.org/10.1016/j.ejca.2022.03.016","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2022.03.016","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},{"id":"pmid:35922251","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35922251","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of cancer (Oxford, England : 1990)","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:lirias2repo.kuleuven.be:20.500.12942/714637","doi":null,"is_oa":true,"landing_page_url":"https://lirias.kuleuven.be/handle/20.500.12942/714637","pdf_url":"https://lirias.kuleuven.be/retrieve/7d0dbe97-6239-4b96-9178-b0989b6fe691","source":{"id":"https://openalex.org/S4306401954","display_name":"Lirias (KU Leuven)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I99464096","host_organization_name":"KU Leuven","host_organization_lineage":["https://openalex.org/I99464096"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"European Journal Of Cancer, vol. 174, (299-309)","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1016/j.ejca.2022.03.016","doi":"https://doi.org/10.1016/j.ejca.2022.03.016","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2022.03.016","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320311653","display_name":"Taiho Pharmaceutical","ror":"https://ror.org/02v50dx14"},{"id":"https://openalex.org/F4320314128","display_name":"Les Laboratories Pierre Fabre","ror":"https://ror.org/04hdhz511"},{"id":"https://openalex.org/F4320315087","display_name":"Clovis Oncology","ror":"https://ror.org/04ps4d441"},{"id":"https://openalex.org/F4320316900","display_name":"Deciphera Pharmaceuticals","ror":"https://ror.org/038hbfs18"},{"id":"https://openalex.org/F4320316932","display_name":"Mersana Therapeutics","ror":"https://ror.org/05jyg6z06"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320318267","display_name":"NuCana","ror":"https://ror.org/039ks3037"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320327811","display_name":"PharmaMar","ror":"https://ror.org/02h694m69"},{"id":"https://openalex.org/F4320327845","display_name":"Ono Pharmaceutical","ror":"https://ror.org/022jefx64"},{"id":"https://openalex.org/F4320330626","display_name":"Geistlich Pharma","ror":"https://ror.org/055f9sm34"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332200","display_name":"EMD Serono","ror":"https://ror.org/027zrs220"},{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4288950951.pdf","grobid_xml":"https://content.openalex.org/works/W4288950951.grobid-xml"},"referenced_works_count":20,"referenced_works":["https://openalex.org/W1947168884","https://openalex.org/W2015584911","https://openalex.org/W2015992811","https://openalex.org/W2033433258","https://openalex.org/W2078032294","https://openalex.org/W2106458953","https://openalex.org/W2137971505","https://openalex.org/W2523715715","https://openalex.org/W2599228863","https://openalex.org/W2792113799","https://openalex.org/W2890539480","https://openalex.org/W2913001220","https://openalex.org/W2925815206","https://openalex.org/W2972117663","https://openalex.org/W2986446283","https://openalex.org/W3032630157","https://openalex.org/W3080145142","https://openalex.org/W3128646645","https://openalex.org/W4210971182","https://openalex.org/W6758571314"],"related_works":["https://openalex.org/W3201697427","https://openalex.org/W4406238848","https://openalex.org/W3209066466","https://openalex.org/W4210971182","https://openalex.org/W4402859640","https://openalex.org/W4214708573","https://openalex.org/W3030495851","https://openalex.org/W4229369556","https://openalex.org/W4295817549","https://openalex.org/W7129363873"],"abstract_inverted_index":{"BACKGROUND:":[0],"In":[1,130],"a":[2],"phase":[3],"III,":[4],"randomised,":[5],"active-controlled":[6],"study":[7],"(EMPOWER-Cervical":[8],"1/GOG-3016/ENGOT-cx9;":[9],"R2810-ONC-1676;":[10],"NCT03257267)":[11],"and":[12,72,97,119,154,181,196,206,223,241,252],"cemiplimab":[13,50,142,166,212,246],"significantly":[14,140],"improved":[15],"survival":[16],"versus":[17],"investigator's":[18,58],"choice":[19,59],"of":[20,60,74,77,94],"chemotherapy":[21,61,227],"among":[22,228],"patients":[23,111,114,121,229],"with":[24,186,226,230,234],"recurrent":[25,231],"cervical":[26,232],"cancer":[27],"who":[28],"had":[29,115,122],"progressed":[30],"on":[31],"platinum-based":[32],"therapy.":[33],"Here":[34],"we":[35],"report":[36],"patient-reported":[37],"outcomes":[38],"in":[39,62,89,104,143,167,178,191,198,213,221,236,247],"this":[40],"pivotal":[41],"study.":[42],"METHODS:":[43],"Patients":[44,65],"were":[45,101,127],"randomised":[46],"1:1":[47],"to":[48,208],"open-label":[49],"(350":[51],"mg":[52],"intravenously":[53],"every":[54],"3":[55],"weeks)":[56],"or":[57],"6-week":[63],"cycles.":[64],"completed":[66],"the":[67,105,131],"European":[68],"Organisation":[69],"for":[70],"Research":[71],"Treatment":[73,163],"Cancer":[75],"Quality":[76],"Life":[78],"Questionnaire-Core":[79],"30":[80],"during":[81],"cycles":[82],"1-16.":[83],"Least-squares":[84],"mean":[85],"changes":[86,175],"from":[87,176],"baseline":[88,177],"global":[90],"health":[91],"status":[92],"(GHS)/quality":[93],"life":[95],"(QoL)":[96],"physical":[98],"functioning":[99,180],"(PF)":[100],"secondary":[102],"end-points":[103],"statistical":[106],"hierarchy.":[107],"RESULTS:":[108],"Of":[109],"608":[110],"(304/arm),":[112],"77.8%":[113],"squamous":[116,132],"cell":[117,133],"carcinoma":[118,134],"22.2%":[120],"adenocarcinoma.":[123],"Questionnaire":[124],"completion":[125],"rates":[126],"\u223c90%":[128],"throughout.":[129],"population,":[135],"overall":[136],"between-group":[137],"differences":[138,164,190,220,244],"statistically":[139],"favoured":[141,165,184,211],"GHS/QoL":[144,222],"(8.49;":[145],"95%":[146,157],"confidence":[147],"interval":[148],"[CI]:":[149],"3.77-13.21;":[150],"P":[151,160],"=":[152],"0.0003)":[153],"PF":[155,224,237],"(8.35;":[156],"CI:":[158],"4.08-12.62;":[159],"<":[161],"0.0001).":[162],"both":[168,199,214],"histologic":[169],"populations":[170],"by":[171,238],"cycle":[172,239],"2.":[173],"Overall":[174],"most":[179],"symptom":[182],"scales":[183],"cemiplimab,":[185],"clinically":[187,242],"meaningful":[188,243],"treatment":[189],"role":[192,248],"functioning,":[193,249],"appetite":[194,250],"loss":[195],"pain":[197],"populations.":[200,215],"The":[201],"sensitivity":[202],"analyses,":[203],"responder":[204],"analyses":[205],"time":[207],"definitive":[209],"deterioration":[210],"CONCLUSIONS:":[216],"Cemiplimab":[217],"conferred":[218],"favourable":[219],"compared":[225],"cancer,":[233],"benefits":[235],"2,":[240],"favouring":[245],"loss,":[251],"pain.":[253]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":12},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":8}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2022-07-31T00:00:00"}